Open AccessPrognostic Role of Cd44 Expression and Neovascularization Determined by Endoglin (Cd105) in Glioblastoma Patients
Author(s) -
Josip Mihić,
Krešimir Rotim,
Majda Vučić,
Ida Hude Dragičević,
Marta Borić,
Liborija Lugović-Mihić
Publication year - 2019
Publication title -
acta clinica croatica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.274
H-Index - 20
eISSN - 1333-9451
pISSN - 0353-9466
DOI - 10.20471/acc.2019.58.03.08
Subject(s) - cd44 , endoglin , neovascularization , medicine , immunohistochemistry , glioblastoma , oncology , pathology , cancer research , angiogenesis , cell , biology , stem cell , genetics , cd34
Glioblastoma multiforme (GBM) is the most common and most aggressive malignant primary brain tumor in humans. Clinically useful molecular markers that help predict response to therapy and prognosis are still rare. The research was conducted in 55 patients with GBM, 26 (47.3%) women and 29 (52.7%) men, mean age 62.58 years. On immunohistochemical analysis, primary antibody to CD44 (dilution 1:50) and primary antibody to endoglin (CD105) (dilution 1:250) were used to evaluate neovascularization. Statistical analysis showed negative correlation between CD44 and survival (p=0.023) (higher expression of CD44 was correlated with shorter survival), but there was no correlation between neovascularization determined by CD105 in GBM and patient survival. Thus, significant individual predictors of longer survival were lower expression of CD44 (p=0.004), higher Karnofsky score (p=0.045), and female gender (p=0.017). The results obtained suggested the possible role of CD44 in the progression and tumor neovascularization of GBM.